Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nkarta, Inc.    NKTX

NKARTA, INC.

(NKTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
34.56(c) 34.85(c) 34.69(c) 35.35(c) 35.27 Last
41 556 47 629 54 460 80 539 3 517 Volume
+1.56% +0.84% -0.46% +1.90% -0.23% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -64,6 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,71x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -73,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 1 152 M 1 152 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 70
Free-Float 85,1%
More Financials
Company
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 03:40pmPräsentation
More about the company
All news about NKARTA, INC.
11/12NKARTA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/12NKARTA, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
11/12NKARTA : Reports Third Quarter 2020 Financial Results
AQ
11/12NKARTA : Announces Treatment of First Patient in First-in-Human Clinical Trial o..
AQ
11/12Nkarta Reports Third Quarter 2020 Financial Results
GL
11/12Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial ..
GL
11/09NKARTA : Announces Presentation of Preclinical Data on NKX019, Engineered NK Cel..
AQ
11/09Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Ce..
GL
11/05NKARTA : Announces November & December 2020 Investor Conference Schedule
AQ
11/05Nkarta Announces November & December 2020 Investor Conference Schedule
GL
10/05NKARTA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosu..
AQ
10/05NKARTA : Announces Leadership Changes
AQ
10/05Nkarta Announces Leadership Changes
GL
09/29NKARTA : Announces October 2020 Investor Conference Schedule
AQ
09/29Nkarta Announces October 2020 Investor Conference Schedule
GL
More news
News in other languages on NKARTA, INC.

- No features available -

More news
Chart NKARTA, INC.
Duration : Period :
Nkarta, Inc. Technical Analysis Chart | NKTX | US65487U1088 | MarketScreener
Technical analysis trends NKARTA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 43,33 $
Last Close Price 35,35 $
Spread / Highest target 55,6%
Spread / Average Target 22,6%
Spread / Lowest Target -3,82%
EPS Revisions
Managers
NameTitle
Paul J. Hastings President, Chief Executive Officer & Director
Ali Behbahani Chairman
Nadir Mahmood CFO, Chief Accounting & Business Officer
Ralph Brandenberger Vice President-Technical Operations
James Trager Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
NKARTA, INC.0.00%1 152
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273